Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319111 | 0.93 | MAPK1 (0.47) | BRD4KDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL3645840 | 0.83 | GSK3A (0.45) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL5480653 | 0.83 | PLA2G10 (0.40) | KDM4EMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL3689858 | 0.82 | BRD4 (0.41) | BRD4KDM4ESMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3693041 | 0.80 | BRD4 (0.39) | BRD4KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL7458942 | 0.79 | ALDH1A1 (0.37) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL24455951 | 0.79 | CACNA1H (0.36) | KDM4ESMN1; SMN2ALDH1A1OPRL1 | |
| SCHEMBL14441118 | 0.78 | BRD4 (0.35) | BRD4ALDH1A1OPRL1 | |
| SCHEMBL7647959 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL24249167 | 0.77 | MAPK1 (0.44) | KDM4EMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220386644-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2022-12-08 | — | — | US | disclosed |
| US-20170231248-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3171703-A1 | USE OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN FOODS CONTAINING UNSWEETENED COCOA | Aharonian, Gregory (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016118806-A1 | USES OF COCA LEAF TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (GB) | 2016-07-28 | — | — | WO | disclosed |
| US-20160021906-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2016014114-A1 | USE OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN FOODS CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015013679-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN FOODS CONTAINING UNSWEETENED CACAO | AHARONIAN GREGORY (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-6660863-B2 | Reacting an cycloheptatriene nitrile compound with nortropane compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| US-6596868-B2 | Reacting a cycloheptatriene derivative with a primary amine or ammonia in the presence of a base | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-06-12 | — | — | US | disclosed |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| US-6486323-B1 | Process for producing optically active tropinonemonocarboxylic acid derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1127887-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2001-08-29 | — | — | EP | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | BRD4 2556/4885KDM4E 848/4885SMN1; SMN2 4071/4885 |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | BRD4 4052/4885KDM4E 1007/4885SMN1; SMN2 3466/4885 |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | BRD4 2556/4885KDM4E 848/4885SMN1; SMN2 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.